| 1 |
32047440 | Phenprocoumon Dose Requirements, Dose Stability and Time in Therapeutic Range in Elderly Patients With CYP2C9 and VKORC1 Polymorphisms. | 2019 |
1 |
| 2 |
29794812 | Genetic causes of resistance to vitamin K antagonists in Polish patients: a novel p.Ile123Met mutation in VKORC1 gene. | 2018 Jul |
1 |
| 3 |
28063245 | Dosing algorithms for vitamin K antagonists across VKORC1 and CYP2C9 genotypes. | 2017 Mar |
1 |
| 4 |
28284562 | The VKORC1 and CYP2C9 genotypes significantly effect Vitamin K antagonist dosing only in patients over the age of 20years. | 2017 Sep |
1 |
| 5 |
28608988 | Dosing algorithms for vitamin K antagonists across VKORC1 and CYP2C9 genotypes: comment. | 2017 Aug |
1 |
| 6 |
28834238 | Long-term outcomes of elderly patients with CYP2C9 and VKORC1 variants treated with vitamin K antagonists. | 2017 Nov |
1 |
| 7 |
27142473 | Pharmacogenomics in Pediatric Patients: Towards Personalized Medicine. | 2016 Aug |
1 |
| 8 |
27462768 | Development of neuro-fuzzy model to explore gene-nutrient interactions modulating warfarin dose requirement. | 2016 Aug |
2 |
| 9 |
25758405 | The impact of genetics on the management of patients on warfarin awaiting surgery. | 2015 Jul |
1 |
| 10 |
25946405 | Variation in genes controlling warfarin disposition and response in American Indian and Alaska Native people: CYP2C9, VKORC1, CYP4F2, CYP4F11, GGCX. | 2015 Jul |
1 |
| 11 |
25042728 | Genetic determinants of acenocoumarol and warfarin maintenance dose requirements in Slavic population: a potential role of CYP4F2 and GGCX polymorphisms. | 2014 Sep |
1 |
| 12 |
25142093 | Influence of proton pump inhibitors and VKORC1 mutations on CYP2C9-mediated dose requirements of vitamin K antagonist therapy: a pilot study. | 2014 Nov |
3 |
| 13 |
23159229 | The influence of VKORC1 and CYP2C9 gene sequence variants on the stability of maintenance phase warfarin treatment. | 2013 Feb |
1 |
| 14 |
23276529 | Repeated bleeding complications during therapy with vitamin K antagonists in a patient with the VKORC1*2A and the CYP2C9*3/*3 alleles: genetic testing to support switching to new oral anticoagulants. | 2013 Mar |
1 |
| 15 |
23588782 | Applications of CYP450 testing in the clinical setting. | 2013 Jun |
1 |
| 16 |
23651023 | Impact of CYP2C9 polymorphisms on the vulnerability to pharmacokinetic drug-drug interactions during acenocoumarol treatment. | 2013 May |
1 |
| 17 |
21883387 | Impact of genetic factors (VKORC1, CYP2C9, CYP4F2 and EPHX1) on the anticoagulation response to fluindione. | 2012 Mar |
2 |
| 18 |
22966889 | Cost-effectiveness of pharmacogenetics in anticoagulation: international differences in healthcare systems and costs. | 2012 Sep |
1 |
| 19 |
28520347 | Warfarin Therapy and VKORC1 and CYP Genotype | 2012 |
1 |
| 20 |
20205664 | Pharmacogenetics of oral anticoagulant therapy. | 2010 |
1 |
| 21 |
22134997 | [Optimalisation of treatment with vitamin K antagonists--the role of gene polymorphisms]. | 2010 |
2 |
| 22 |
19297519 | CYP4F2 is a vitamin K1 oxidase: An explanation for altered warfarin dose in carriers of the V433M variant. | 2009 Jun |
1 |
| 23 |
19484231 | Severely diminished response to vitamin K-treatment for self-inflicted warfarin intoxication in a patient genotyped as CYP2C9*3*3. | 2009 Oct |
1 |
| 24 |
17955831 | [Oral anticoagulation and pharmacogenetics: importance in the clinical setting]. | 2007 Sep 12 |
3 |
| 25 |
16863464 | Contribution of CYP2C9 to variability in vitamin K antagonist metabolism. | 2006 Feb |
3 |
| 26 |
17042764 | Appraisal of current vitamin K dosing algorithms for the reversal of over-anticoagulation with warfarin: the need for a more tailored dosing regimen. | 2006 Dec |
1 |
| 27 |
29793229 | The CYP2C9 polymorphism: from enzyme kinetics to clinical dose recommendations. | 2004 Dec |
1 |
| 28 |
11452703 | Effects of oral vitamin K on S- and R-warfarin pharmacokinetics and pharmacodynamics: enhanced safety of warfarin as a CYP2C9 probe. | 2001 Jul |
1 |